follows: Unit: Million Baht Revenue Structure Q3/2019 Q3/2018 Change General Patient Revenue 1,683.8 1,518.9 164.9 10.9% Social Security Scheme Revenue 785.4 709.1 76.3 10.8% Other Revenue 31.3 26.3 5.0
the performance and the financial status for the year 2019 ended December 31, 2019 of the Company and its subsidiaries, as shown below: (Unit : Thousand Baht) 2019 2018 Change %Change Revenue 910,707
results for the nine-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech
: Million Baht For the 3 months Change between QoQ Change between YoY For the 6 months Change between YoY Q2/17 Q1/17 Q2/16 Amount % Amount % Q2/17 Q2/16 Amount % Revenues from medical services 92.86 88.86
, consists of unrealised gain on exchange rate of receivable under finance lease agreement, gain on forward contracts and insurance claim. Change QoQ Consolidated financial statements Change YOY Financial
Summary of operations and the factors that make a significant change Summary of Operations for the Year 2022 Operation Overview Annual Balance Change 2022 2021 2022 VS 2021 Million baht (MB) (MB) % Total
Q1/2020 due to higher franchise royalty fee from Mikka Café as a result of franchise expansion. Q1/2021 vs Q1/2020YoY Revenue Q1/20 Q1/21 Change +/(-) (THB million) YoY Revenue from Dessert Café 204
million baht, an increase of 141.61 million baht or 16.30%. Interest expenses were 225.39 million baht, an increase of 11.87 million baht or 5.56%. The increasing was due to additional low cost of borrowing
period of last year The explanation for Company’s Operation change from same period more than 20% To : The President, The Stock Exchange of Thailand T.C.J. Asia Public Company Limited (“TCJ”) and its
compared with net loss of Baht 7.38 million on Baht 6.81 million revenues over the same period in 2016. The change in loss for the quarterly operating result ended on June 30, 2017 is due to higher revenues